Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...

Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

Galderma has reported new interim analysis data from the OLYMPIA trial of Nemluvio for the moderate-to-severe prurigo ...

An expert from a CRO-SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory ...

AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

Patient-centric approaches such as AI and decentralised trials are improving oncology trial enrolment, but 2025 has given ...

Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating NSCLC ...

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in ...